Genopore
Rehovot, Israel· Est.
A platform for rapid, single‑molecule protein detection using nanopore‑based optical readout.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $150M
AI Company Overview
A platform for rapid, single‑molecule protein detection using nanopore‑based optical readout.
DiagnosticsDrug DiscoveryPrecision Medicine
Technology Platform
Chemo‑selective protein labeling combined with solid‑state nanopore translocation and AI‑driven optical detection for single‑molecule, full‑length protein identification.
Opportunities
Scaling the platform for clinical diagnostics and partnering with pharma for biomarker discovery could unlock large, recurring revenue streams.
Risk Factors
Technology adoption risk, competition from established mass‑spec and emerging nanopore proteomics firms, and regulatory hurdles for diagnostic approval.
Competitive Landscape
Genopore differentiates itself from mass spectrometry and affinity‑based assays through single‑molecule optical readout, but faces competition from other nanopore proteomics startups and advanced MS platforms.